Not available
Quote | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Last: | $28.19 |
---|---|
Change Percent: | -1.24% |
Open: | $29.3 |
Close: | $28.19 |
High: | $29.595 |
Low: | $28.12 |
Volume: | 847,114 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
2024-07-26 12:12:56 ET Summary Arrowhead Pharmaceuticals has a promising pipeline of drug candidates based on RNAi methodology. It has developed a tighter focus to push its most promising cardiometabolic drug (Plozasiran) toward FDA approval and commercialization. The new focu...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
Message Board Posts | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ARWR News Article - Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday | whytestocks | investorshangout | 04/25/2023 3:35:46 PM |
$ARWR still ascending. | MiamiGent | investorshub | 01/13/2023 4:36:57 PM |
whytestocks: $ARWR News Article - Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment | whytestocks | investorshangout | 12/20/2022 4:25:49 PM |
Arrowhead is an amazing company. Gene silencing | jimmy667 | investorshub | 10/22/2022 8:11:09 AM |
whytestocks: $ARWR News Article - 5 Top Biotech Stocks To Watch In July 2022 | whytestocks | investorshangout | 06/30/2022 6:55:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...